American Century Companies Inc. acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 36,423 shares of the company’s stock, valued at approximately $583,000. American Century Companies Inc. owned 0.10% of Intellia Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently modified their holdings of the business. Schwab Charles Investment Management Inc. raised its position in shares of Intellia Therapeutics by 6.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 26,903 shares of the company’s stock worth $380,000 after acquiring an additional 1,539 shares during the period. Bank of New York Mellon Corp raised its position in shares of Intellia Therapeutics by 5.6% in the first quarter. Bank of New York Mellon Corp now owns 31,676 shares of the company’s stock worth $446,000 after acquiring an additional 1,682 shares during the period. Geode Capital Management LLC raised its position in shares of Intellia Therapeutics by 6.0% in the first quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock worth $1,072,000 after acquiring an additional 4,291 shares during the period. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics in the second quarter worth about $101,000. Finally, Bank of Montreal Can raised its position in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after acquiring an additional 7,222 shares during the period. Institutional investors and hedge funds own 46.52% of the company’s stock.

A number of brokerages have weighed in on NTLA. Barclays PLC began coverage on shares of Intellia Therapeutics in a research report on Wednesday, September 6th. They issued an “overweight” rating and a $29.00 price objective for the company. Chardan Capital downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research report on Tuesday, August 29th. Cann reiterated a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. began coverage on shares of Intellia Therapeutics in a research report on Tuesday, July 18th. They issued a “market perform” rating for the company. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a research report on Saturday, July 22nd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $25.43.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/19/american-century-companies-inc-acquires-new-stake-in-intellia-therapeutics-inc-ntla.html.

In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 12.80% of the company’s stock.

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) opened at 22.81 on Tuesday. Intellia Therapeutics, Inc. has a 1-year low of $10.83 and a 1-year high of $23.58. The stock’s market cap is $823.71 million. The stock’s 50 day moving average is $22.13 and its 200-day moving average is $20.95.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.03). The firm had revenue of $5.90 million during the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business’s revenue for the quarter was up 40.5% on a year-over-year basis. On average, analysts predict that Intellia Therapeutics, Inc. will post ($1.78) EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Stock Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related stocks with our FREE daily email newsletter.